Biotalys NV · EURONEXT:BTLS
Biotalys NV — Investor Presentation (August 2023)
31 slides from Biotalys NV's investor presentation, August 2023
Slide 1: Shaping a sustainable and safe food supply
Shaping a sustainable and safe food supply 1
Slide 2: Safe harbor statement
Safe harbor statement This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotalys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve info
Slide 3: Biotalys' ambition
Biotalys’ ambition Provide safe and sustainable alternatives to protect our food, ensure productivity and quality while preserving our environment, our soils and our health Challenges Requirements Biotalys’ solutions Differentiated and versatile 10b population by 20501 biocontrol platform Secure yie
Slide 4: Key facts
Key facts First product Founded in 2013 Belgium and US Close to 20 patent ready for market 75 FTEs1 introduction, IPO in 2021 locations families1 pending regulatory approval Agricultural Technology company Developing novel protein-based The first product Evoca™,2 aims to focused on addressing food b
Slide 5: Crop protection: a growing market
Crop protection: a growing market Total Crop Protection Market 20212 Regional Estimated evolution1 Estimated Crop Protection Region 2021 2022E Change 29% 25% market Asia Pacific 21.0 21.9 +4% 2022: $69.2b (+6.2%) 1 Latin America 16.4 19.2 +16.9% ~ $65B 2025E: $75b Europe, ME 16.3 15.7 -3.6% 13% and
Slide 6: Advantages of biological crop protection products drive a strong growing market
NOT FOR DISTRIBUTION Advantages of biological crop protection products drive a strong growing market Advantages of biologicals vs. chemicals Biological CP market expected to show double digit growth over Increase quality & safety Provide new tools Provide safe & the next years of produce by limiting
Slide 7: Biocontrol technology maturity to expand market potential
Biocontrol technology maturity to expand market potential Market Acceptance In Development On the Market Companies (extract) Time Proteins / Peptides / Enzymes Microbials Technologies Plant Extracts RNA Other Biochemicals Pheromones 7
Slide 8: AGROBODY: Biocontrol by Biotalys
AGR@BODY” iocontrol by biotalys
Slide 9: AGROBODY Foundry – validated platform for antibody-based biocontrols
AGROBODY™ Foundry – validated platform for the generation of antibody-based biocontrols Similar affinity to conventional antibodies Single domain antibodies engineered from heavy-chain antibodies exploited for >25 years → High binding capacity to selected antigens VHH High stability Heavy-chain anti
Slide 10: AGROBODY Foundry – nature driven, designed for performance
AGROBODY FoundryTM – nature driven, designed for performance Current key crop pest and disease targets Targeted Discovery (High Throughput) Field Straightforward Delivery Development Regulatory Path Fungi Protein libraries VHH Insects Novel biocontrols Bacteria for a wide range of pests and diseases
Slide 11: AGROBODY Foundry combines the best of both worlds
AGROBODY Foundry™ combines the best of both worlds Sustainability Performance Discovery A numbers game Scalability Efficiency5 Consistency 108 Antibodies Thousands of hits ~€35m2 Multiple potential leads & diverse MoA ~8 years3 100,000 Synthesis €250m1 Chemicals 1 Lead + Backups (same MoA) 11 years1
Slide 12: Evoca is pending registration
EvocaTM is pending registration. This product is not currently registered for sale or use in the United States, the EU or elsewhere, and 12 is not being offered for sale.
Slide 13: Evoca: a novel tool for biocontrol
NOT FOR DISTRIBUTION Evoca™: a novel tool for biocontrol Performance on par with Contact activity for preventive synthetic chemical standards in IPM*- control of Botrytis cinerea and programs1 powdery mildew New mode-of-action for resistance Up to 2/3 of residue reduction in management: replacement
Slide 14: Field trials: Evoca, true replacer for a leading chemical
NOT FOR DISTRIBUTION Field trials: Evoca™, true replacer for a leading chemical Percent control of harvest bunch severity, relative to untreated controls 2021 8 trials 2022 18 trials A B C flowering bunch veraison closure Chemical fungicides Active Ingredient(s) FRAC A cyprodinil + fludioxonil 9 + 1
Slide 15: Evoca - significant progress
NOT FOR DISTRIBUTION Evoca™ - significant progress ✓ Successful field trial results, further demonstrating Evoca’s efficacy and uniqueness ✓ New trials now ongoing in hemp and blueberries, where demand for safe and sustainable solutions is strong and value is high ✓ Preparation of market calibration
Slide 16: Independent field trials by US public institutes
Independent field trials by US public institutes Continued demonstration of performance and consistency in independent IPM programs Untreated EVOCA™ Leading biocontrol IPM Grape – Botrytis bunch rot UC Davis Cooperative Extension Dr. Akif Eskalen Notes: IPM: Mevalone (3 plant terpenes) fb Pristine (
Slide 17: Update on regulatory process and timelines for Evoca
NOT FOR DISTRIBUTION Update on regulatory process and timelines for Evoca™ ✓ Review by the U.S. Environmental Protection Agency ✓ Review by the Board for Authorisation of Plant Protection (EPA) is ongoing and Biotalys is working with the Products in the NL (CTGB) is ongoing and Biotalys is authority
Slide 18: Product Pipeline
Product Pipeline
Slide 19: Innovative pipeline of protein-based biocontrols
Innovative pipeline of protein-based biocontrols Target Program Total Addressable Stage Target Crops Partnerships Market: $4.8bn2 Launch3 Botrytis, Powdery mildew Market calibration 2024 Botrytis, Powdery mildew $600m 2026 Botrytis, Powdery mildew, Anthracnose BioFun-61 $1.2bn 2028 Lepidoptera BioIn
Slide 20: Partnerships expanding validation and scope of technology
NOT FOR DISTRIBUTION Partnerships expanding validation and scope of technology • Research into leafspot disease for cowpeas • Strategic partnership leveraging Biotalys’ supporting smallholders’ livelihood AGROBODYTM Platform • Targeting discovery of a new, safe and efficient • Focused on protein-bas
Slide 21: Continued exploration of potential applications throughout the food value chain
Continued exploration of potential applications throughout the food value chain Seed treatment Around harvest Retail Crop Protection Post-harvest Covered Other crops Segments ... Ag Industry Majors Food Protection Retail Distributors Shipper Packers Consumers Biocontrol Specialists Integrated Food I
Slide 22: Manufacturing and platform optimizations delivering a profitable pipeline
NOT FOR DISTRIBUTION Manufacturing and platform optimizations delivering a profitable pipeline Production efficiency 1 Protein expression + process optimization Production costs Economies of scale 2 Campaign run in larger bioreactors Towards Evoca commercial Rate reduction 1 3 Intrinsic activity + f
Slide 23: De-risk, accelerate and grow through strategic partnerships
De-risk, accelerate and grow through strategic partnerships Science and Technology Product Development Distribution Exclusive US Pipeline Product Manufacturing Regulatory 23 23
Slide 24: Financials
Financials reinventing food protection
Slide 25: Key financials – HY 2023
Key financials – HY 2023 In € thousand June 30, 2023 June 30, 2022 Other operating income 1,318 1,140 Research and development expenses (8,661) (7,574) General and administrative expenses (2,771) (2,596) Marketing expenses (741) (718) Operating loss (10,855) (9,748) Loss for the period (10,664) (9,8
Slide 26: Biotalys' participation at upcoming investor events
NOT FOR DISTRIBUTION Biotalys’ participation at upcoming investor events Food & World Investor AgTech Global Canaccord Biotalys VFB Shareholders Chemicals AgriTech Access Answers Agricultural AgrifoodTech Biotech Event Club Conference 26-27 Conference Conference Forum Conference 16 November 12 Decem
Slide 27: Listed on Euronext Brussels
Listed on Euronext Brussels Code: Analyst coverage: BTLS Gimv 13.4 % Guy Sips KBC Securities Sofinnova 13.2 % AvH 12.5 % Christian Faitz PMV 7.8 % Kepler Cheuvreux AIF 9.2 % Sebastian Bray Shareholder RMM 5.7 % Berenberg structure Madeli 6.1 % K&E 5.8 % Other 26.3 % Percentages rounded – non diluted
Slide 28: Outlook: continuous value creation with major milestones
Outlook: continuous value creation with major milestones • Obtain product approval in the U.S., paving the way to advance the rest of Biotalys’ pipeline through the regulatory process • Initiate multi-year market calibration in the U.S. with partner Biobest for highest fruit & vegetable market segme
Slide 29: Team of professionals with extensive industry experience
Team of professionals with extensive industry experience Patrice Sellès Luc Maertens Douglas Minder Carlo Boutton Patrick McDonnell CEO COO CFO CSO CBO Simon E. Moroney Michiel van Lookeren Piet Bevernage Johan Cardoen Chairman Campagne Non-Executive Director Independent Director Independent Directo
Slide 30: IR@biotalys.com www.biotalys.com
IR@biotalys.com www.biotalys.com
Slide 31: Value creation designed through pipeline advancement, strategic partnerships & commercial growth
Value creation designed through pipeline advancement, strategic key partnerships & commercial growth Sales In-licensing growth to accelerate and market AGROBODY growth expansion Pipeline Foundry™ progression expansion Strategic R&D and Evoca™ partnerships expansion registration Strategic production